Selumetinib Aids Short-Term Outcomes in Uveal Melanoma

This article originally appeared here.
Selumetinib Aids Short-Term Outcomes in Uveal Melanoma
Selumetinib Aids Short-Term Outcomes in Uveal Melanoma

(HealthDay News) — For patients with advanced uveal melanoma, selumetinib treatment is associated with modestly improved progression-free survival and response rates, but no improvement in overall survival compared to chemotherapy, according to a study published June 18 in the Journal of the American Medical Association.

Richard D. Carvajal, MD, from Memorial Sloan-Kettering Cancer Center in New York, and colleagues randomized 101 patients (1:1) with metastatic uveal melanoma to receive selumetinib, 75mg orally twice daily on a continual basis (n=50), or chemotherapy (temozolomide, 150mg/m2 orally daily for 5 of every 28 days, or dacarbazine, 1,000mg/m2 intravenously every 21 days [investigator choice]; (n=51) until disease progression, death, intolerable adverse effects, or withdrawal of consent.

The researchers found that median progression-free survival among patients randomized to chemotherapy was seven weeks and was 15.9 weeks among those randomized to selumetinib (hazard ratio [HR],0.46; P<.001). With chemotherapy median overall survival time was 9.1 months and was 11.8 months with selumetinib (HR, 0.66; 95% CI, 0.41–1.06; P=.09). There were no objective responses seen with chemotherapy, while 49% of patients treated with selumetinib achieved tumor regression and 14% achieving an objective radiographic response to therapy. The majority of patients treated with selumetinib (97%) had treatment-related adverse events, with 37% requiring at least 1 dose reduction.

"Improvement in clinical outcomes was accompanied by a high rate of adverse events," the authors write.

Several authors disclose financial ties to the pharmaceutical industry, and one author reports receiving travel reimbursements from AstraZeneca, manufacturer of selumetinib.

Full Text (subscription or payment may be required)